EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Hereditary cancer syndromes

Evgeny N Imyanitov, Ekaterina S Kuligina, Anna P Sokolenko, Evgeny N Suspitsin, Grigoriy A Yanus, Aglaya G Iyevleva, Alexandr O Ivantsov, Svetlana N Aleksakhina

World Journal of Clinical Oncology · 24.02.2023 · 14 (2) · 40-68

DOI: 10.5306/wjco.v14.i2.40 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift World Journal of Clinical Oncology, online erschienen am 24.02.2023. Verfasst von Evgeny N Imyanitov und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, St.-Petersburg 197758, Russia. Die Arbeit wurde bisher 78-mal zitiert (Crossref) und nennt 241 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hereditary cancer syndromes (HCSs) are arguably the most frequent category of Mendelian genetic diseases, as at least 2% of presumably healthy subjects carry highly-penetrant tumor-predisposing pathogenic variants (PVs). Hereditary breast-ovarian cancer and Lynch syndrome make the highest contribution to cancer morbidity; in addition, there are several dozen less frequent types of familial tumors. The development of the majority albeit not all hereditary malignancies involves two-hit mechanism, i.e. the somatic inactivation of the remaining copy of the affected gene. Earlier studies on cancer families suggested nearly fatal penetrance for the majority of HCS genes; however, population-based investigations and especially large-scale next-generation sequencing data sets demonstrate that the presence of some highly-penetrant PVs is often compatible with healthy status. Hereditary cancer research initially focused mainly on cancer detection and prevention. Recent studies identified multiple HCS-specific drug vulnerabilities, which translated into the development of highly efficient therapeutic options.

Schlagwörter

Stichwörter der Autor:innen

Cancer predispositionCancer treatmentGermline pathogenic variantsHereditary cancer syndromesNext-generation sequencing

Autor:innen und Institutionen

  • Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, St.-Petersburg 197758, Russia.
  • Department of Clinical Genetics, St.-Petersburg Pediatric Medical University, St.-Petersburg 194100, Russia.
  • Department of Clinical Genetics, St.-Petersburg Pediatric Medical University, St.-Petersburg 194100, Russia. evgeny@imyanitov.spb.ru.

Zitieren

APA

Imyanitov, E. N., Kuligina, E. S., Sokolenko, A. P., Suspitsin, E. N., Yanus, G. A., Iyevleva, A. G., Ivantsov, A. O., & Aleksakhina, S. N. (2023). Hereditary cancer syndromes. World Journal of Clinical Oncology, 14(2), 40-68. https://doi.org/10.5306/wjco.v14.i2.40

Vancouver

Imyanitov EN, Kuligina ES, Sokolenko AP, Suspitsin EN, Yanus GA, Iyevleva AG, et al. Hereditary cancer syndromes. World Journal of Clinical Oncology. 2023;14(2):40-68. doi:10.5306/wjco.v14.i2.40

BibTeX
@article{Imyanitov2023,
  author = {Imyanitov, Evgeny N and Kuligina, Ekaterina S and Sokolenko, Anna P and Suspitsin, Evgeny N and Yanus, Grigoriy A and Iyevleva, Aglaya G and Ivantsov, Alexandr O and Aleksakhina, Svetlana N},
  title = {Hereditary cancer syndromes},
  journal = {World Journal of Clinical Oncology},
  year = {2023},
  volume = {14},
  number = {2},
  pages = {40--68},
  doi = {10.5306/wjco.v14.i2.40}
}
Kostenlos starten →